文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脑出血后抗凝逆转的时间与预后

Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage.

作者信息

Sheth Kevin N, Solomon Nicole, Alhanti Brooke, Messe Steven R, Xian Ying, Bhatt Deepak L, Hemphill J Claude, Frontera Jennifer A, Chang Raymond C, Danelich Ilya M, Huang Joanna, Schwamm Lee, Smith Eric E, Goldstein Joshua N, Mac Grory Brian, Fonarow Gregg C, Saver Jeffrey L

机构信息

Yale Center for Brain and Mind Health, Yale University School of Medicine, New Haven, Connecticut.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

出版信息

JAMA Neurol. 2024 Feb 9;81(4):363-72. doi: 10.1001/jamaneurol.2024.0221.


DOI:10.1001/jamaneurol.2024.0221
PMID:38335064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11002694/
Abstract

IMPORTANCE: Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether there is a time-dependent treatment effect for door-to-treatment (DTT) times in clinical practice. OBJECTIVE: To evaluate whether DTT time is associated with outcome among patients with anticoagulation-associated ICH treated with reversal interventions. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the American Heart Association Get With The Guidelines-Stroke quality improvement registry. Patients with ICH who presented within 24 hours of symptom onset across 465 US hospitals from 2015 to 2021 were included. Data were analyzed from January to September 2023. EXPOSURES: Anticoagulation-associated ICH. MAIN OUTCOMES AND MEASURES: DTT times and outcomes were analyzed using logistic regression modeling, adjusted for demographic, history, baseline, and hospital characteristics, with hospital-specific random intercepts to account for clustering by site. The primary outcome of interest was the composite inpatient mortality and discharge to hospice. Additional prespecified secondary outcomes, including functional outcome (discharge modified Rankin Scale score, ambulatory status, and discharge venue), were also examined. RESULTS: Of 9492 patients with anticoagulation-associated ICH and documented reversal intervention status, 4232 (44.6%) were female, and the median (IQR) age was 77 (68-84) years. A total of 7469 (78.7%) received reversal therapy, including 4616 of 5429 (85.0%) taking warfarin and 2856 of 4069 (70.2%) taking a non-vitamin K antagonist oral anticoagulant. For the 5224 patients taking a reversal intervention with documented workflow times, the median (IQR) onset-to-treatment time was 232 (142-482) minutes and the median (IQR) DTT time was 82 (58-117) minutes, with a DTT time of 60 minutes or less in 1449 (27.7%). A DTT time of 60 minutes or less was associated with decreased mortality and discharge to hospice (adjusted odds ratio, 0.82; 95% CI, 0.69-0.99) but no difference in functional outcome (ie, a modified Rankin Scale score of 0 to 3; adjusted odds ratio, 0.91; 95% CI, 0.67-1.24). Factors associated with a DTT time of 60 minutes or less included White race, higher systolic blood pressure, and lower stroke severity. CONCLUSIONS AND RELEVANCE: In US hospitals participating in Get With The Guidelines-Stroke, earlier anticoagulation reversal was associated with improved survival for patients with ICH. These findings support intensive efforts to accelerate evaluation and treatment for patients with this devastating form of stroke.

摘要

重要性:脑出血(ICH)是最致命的中风亚型,在抗凝相关脑出血中死亡率尤其高。最近,已制定了特定的抗凝逆转策略,但在临床实践中,门到治疗(DTT)时间是否存在时间依赖性治疗效果尚不清楚。 目的:评估在接受逆转干预治疗的抗凝相关脑出血患者中,DTT时间是否与预后相关。 设计、设置和参与者:这项队列研究使用了美国心脏协会“遵循指南-中风”质量改进登记处的数据。纳入了2015年至2021年在美国465家医院症状发作后24小时内就诊的脑出血患者。数据于2023年1月至9月进行分析。 暴露因素:抗凝相关脑出血。 主要结局和测量指标:使用逻辑回归模型分析DTT时间和结局,并对人口统计学、病史、基线和医院特征进行调整,采用医院特定的随机截距来考虑地点聚类。感兴趣的主要结局是住院综合死亡率和临终关怀出院。还检查了其他预先指定的次要结局,包括功能结局(出院时改良Rankin量表评分、活动状态和出院地点)。 结果:在9492例有抗凝相关脑出血且记录了逆转干预状态的患者中,4232例(44.6%)为女性,中位(IQR)年龄为77(68-84)岁。共有7469例(78.7%)接受了逆转治疗,其中服用华法林的5429例中有4616例(85.0%),服用非维生素K拮抗剂口服抗凝剂的4069例中有2856例(70.2%)。对于5224例接受逆转干预且记录了工作流程时间的患者,中位(IQR)发病到治疗时间为232(142-482)分钟,中位(IQR)DTT时间为82(58-117)分钟,1449例(27.7%)的DTT时间为60分钟或更短。DTT时间为60分钟或更短与死亡率降低和临终关怀出院相关(调整后的优势比,0.82;95%CI,0.69-0.99),但在功能结局方面无差异(即改良Rankin量表评分为0至3;调整后的优势比,0.91;95%CI,0.67-1.24)。与DTT时间为60分钟或更短相关的因素包括白人种族、较高的收缩压和较低的中风严重程度。 结论和相关性:在美国参与“遵循指南-中风”的医院中,早期抗凝逆转与脑出血患者生存率提高相关。这些发现支持为这种毁灭性中风形式的患者加速评估和治疗而做出的密集努力。

相似文献

[1]
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage.

JAMA Neurol. 2024-2-9

[2]
Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage.

JAMA Netw Open. 2021-2-1

[3]
Blood Pressure and Anticoagulation Reversal Management during Off-Hours in Oral Anticoagulation-Associated Intracerebral Hemorrhage.

Cerebrovasc Dis. 2020-4-22

[4]
Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.

JAMA. 2018-2-6

[5]
Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.

JAMA. 2019-7-16

[6]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[7]
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants.

JAMA Neurol. 2016-2

[8]
Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

JAMA. 2015-2-24

[9]
Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase.

JAMA. 2022-2-22

[10]
Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

JAMA.

引用本文的文献

[1]
Minimally Invasive and Proactive Approaches for Treatment of Acute Traumatic Brain Injury in Elderly Patients.

J Clin Med. 2025-7-16

[2]
The association between neutrophil lymphocyte ratio and perihematomal edema in cerebral hemorrhage: a multicenter retrospective study.

Front Neurol. 2025-7-4

[3]
Reversal of anticoagulation in patients with intracerebral haemorrhage related to oral anticoagulants: State of the evidence.

Eur Stroke J. 2025-4

[4]
Pharmacist Preparation of 4F-PCC in the Emergency Department: Implications for Hemorrhage Management.

Hosp Pharm. 2025-4-30

[5]
Volume Tolerance and Prognostic Impact of Hematoma Expansion in Deep and Lobar Intracerebral Hemorrhage.

Stroke. 2025-5

[6]
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality.

Res Pract Thromb Haemost. 2025-1-24

[7]
Impact of Pharmacist Preparation of Four-Factor Prothrombin Complex Concentrate at the Bedside in Patients with Life-Threatening Hemorrhage in the Emergency Department.

Hosp Pharm. 2025-2-21

[8]
Reversal of Direct Oral Anticoagulants (DOACs) for Critical Bleeding or Urgent Procedures.

J Clin Med. 2025-2-5

[9]
Intracerebral haemorrhage - mechanisms, diagnosis and prospects for treatment and prevention.

Nat Rev Neurol. 2024-12

[10]
Management of factor Xa inhibitor-related traumatic non-intracranial bleeding events with andexanet alfa or four-factor prothrombin complex concentrate in a US multicenter observational study.

J Am Coll Emerg Physicians Open. 2024-11-7

本文引用的文献

[1]
The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.

Lancet. 2023-7-1

[2]
Spontaneous Intracerebral Hemorrhage.

N Engl J Med. 2022-10-27

[3]
Early Stroke Recognition and Time-based Emergency Care Performance Metrics for Intracerebral Hemorrhage.

J Stroke Cerebrovasc Dis. 2019-12-12

[4]
An Intracerebral Hemorrhage Care Bundle Is Associated with Lower Case Fatality.

Ann Neurol. 2019-8-16

[5]
Clinical Performance Measures for Adults Hospitalized With Intracerebral Hemorrhage: Performance Measures for Healthcare Professionals From the American Heart Association/American Stroke Association.

Stroke. 2018-7

[6]
The American Heart Association's Get With the Guidelines (GWTG)-Stroke development and impact on stroke care.

Stroke Vasc Neurol. 2017-6

[7]
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

N Engl J Med. 2016-9-22

[8]
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.

Lancet Neurol. 2016-4-11

[9]
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.

JAMA Neurol. 2016-1

[10]
Idarucizumab for Dabigatran Reversal.

N Engl J Med. 2015-6-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索